Concepedia

Lisa Mahnke

LM

16

Publications

2.3K

Citations

13

H-Index

2005

Active since

Affiliations

Merck (Germany)(Current)

Washington University in St. Louis

Ono Pharmaceutical (United States)

Tennessee Oncology

Dana-Farber Cancer Institute

Lisa Mahnke is an author at Merck (Germany) specializing in medicine, pathology, and radiation oncology.

Top concepts

Publications per year

2005–2020

16

Publications

16

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

, , +3

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 406 citations · Full text

Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV

Mark Sulkowski, Kenneth E. Sherman, Douglas T. Dieterich et al. · Annals of Internal Medicine · 2013 · 199 citations

Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA

C. Lance Cowey, Lisa Mahnke, Janet L. Espirito et al. · Future Oncology · 2017 · 115 citations · Full text

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

Jürgen C. Becker, Eva Lorenz, Selma Ugurel et al. · Oncotarget · 2017 · 91 citations · Full text

Rows per page

1–5 of 16